The University of Szeged (SZTE) announced a cooperation deal with drugmaker Pfizer Gyógyszerkereskedelmi Kft., which will result in the universityʼs patients being able to access the most modern therapies, according to a report by Szeged.hu.
The announcement notes that the aim of the cooperation is enhancing R&D in the medicine industry, and thus improving the recovery of patients. The cooperation will increase the R&D capacity of SZTE and the number of medicine trials.
SZTE achieved clinical trial center certification under the "Pfizer Inspire" program in October 2018, becoming a part of the companyʼs special network. Pfizer offers clinical trials to members of this network first, meaning that the number of clinical trials sponsored by Pfizer at the university may grow significantly, says Judit Fendler, SZTE chancellor.
Some 35 successful clinical trials have already been conducted at SZTE, with 11 more to follow, primarily in the fields of oncology, and systematic immflamuation. Thanks to the agreement, patients will have access to the most modern and innovative therapies, well before they become widely accessible.
Pfizer, the largest U.S. drugmaker, had an income of USD 53.6 billion in 2018. The firm has been present in Hungary since 1991, with 80 Pfizer products accessible in Hungary, in 200 different forms. The yearly turnover of its Hungarian subsidiary, Pfizer Gyógyszergyári Kft., reached HUF 36 bln in 2017.